Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma

Divaya Bhutani, Jeffrey A Zonder Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA Abstract: The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in part, for the significant increase in the s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bhutani D, Zonder JA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Multiple Myeloma Carfilzomib Relapsed/refractory Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/3d0a108b5d134eb4907426eb0441eb80
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3d0a108b5d134eb4907426eb0441eb80
record_format	dspace
spelling	oai:doaj.org-article:3d0a108b5d134eb4907426eb0441eb802021-12-02T02:09:58ZUse of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma1179-9889https://doaj.org/article/3d0a108b5d134eb4907426eb0441eb802017-07-01T00:00:00Zhttps://www.dovepress.com/use-of-carfilzomib-in-second-line-therapy-and-beyond-for-relapsed-mult-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889Divaya Bhutani, Jeffrey A Zonder Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA Abstract: The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in part, for the significant increase in the survival of patients diagnosed with this disease. Bortezomib was the first proteasome inhibitor to be approved for the therapy of multiple myeloma. Carfilzomib is a second-generation proteasome inhibitor with irreversible binding to proteasome and less off-target toxicity. The drug has been approved for use in relapsed/refractory multiple myeloma. In this article, we review the use of carfilzomib as second-line therapy in multiple myeloma. We also review the current standards of care for relapsed/refractory multiple myeloma, with particular focus on the use of carfilzomib in advanced disease. Keywords: multiple myeloma, carfilzomib, relapsed/refractory Bhutani DZonder JADove Medical PressarticleMultiple MyelomaCarfilzomibRelapsed/refractoryDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol Volume 7, Pp 53-60 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Multiple Myeloma Carfilzomib Relapsed/refractory Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Multiple Myeloma Carfilzomib Relapsed/refractory Diseases of the blood and blood-forming organs RC633-647.5 Bhutani D Zonder JA Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
description	Divaya Bhutani, Jeffrey A Zonder Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA Abstract: The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in part, for the significant increase in the survival of patients diagnosed with this disease. Bortezomib was the first proteasome inhibitor to be approved for the therapy of multiple myeloma. Carfilzomib is a second-generation proteasome inhibitor with irreversible binding to proteasome and less off-target toxicity. The drug has been approved for use in relapsed/refractory multiple myeloma. In this article, we review the use of carfilzomib as second-line therapy in multiple myeloma. We also review the current standards of care for relapsed/refractory multiple myeloma, with particular focus on the use of carfilzomib in advanced disease. Keywords: multiple myeloma, carfilzomib, relapsed/refractory
format	article
author	Bhutani D Zonder JA
author_facet	Bhutani D Zonder JA
author_sort	Bhutani D
title	Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
title_short	Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
title_full	Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
title_fullStr	Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
title_full_unstemmed	Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
title_sort	use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/3d0a108b5d134eb4907426eb0441eb80
work_keys_str_mv	AT bhutanid useofcarfilzomibinsecondlinetherapyandbeyondforrelapsedmultiplemyeloma AT zonderja useofcarfilzomibinsecondlinetherapyandbeyondforrelapsedmultiplemyeloma
_version_	1718402643553943552

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma

Ejemplares similares